Friday, November 20, 2015


A recent report published on November 9 in the Annals of Internal Medicine states the newest findings on the debate considering the safety of the beauty surgery. And, the good thing is the research conducted by Dr Ethan Balk, of the Brown University School of Public Health in Providence, Rhode Island confirmed that silicone breast implants are not linked to any long-term health effects, according to Web Md.

The product, which came in the US market in the 1960s, was questioned and had a moratorium in 1992, when the public raised concerns on the possibility of health risks (e.g. breast cancer, rheumatoid arthritis and fibromyalgia) later on in case of a ruptured silicone implant.
However, they were reintroduced in the market in 2006.
"Owing to inconsistencies among the studies reviewed, further investigation is required to determine whether any true associations exist between silicone gel implants and long-term health outcomes," Dr. Ethan Balk said in a report by Mail Online.
The recent research made use of 5,000 studies investigating the health outcomes of breast augmentation surgery.
Women participants are from North America, Europe and Australia said to have gone under the knife between 1964 and 2003.
Meanwhile, the study did not include to consider other factors like alcohol consumption and smoking. Also, it is criticized for being too general as not to focus on the effects of silicone breast implants, HNGN said.
To answer this, upcoming studies planned to register patients who got the operation and record their health conditions the moment they had the surgery until they decide to replace the implants.
"Hopefully it'll show what the implants do in five, 10 or 15 years, because that's what's lacking in the current data," Dr. Rod Rohrich from the University of Texas Southwestern Medical Center in Dallas said.
In 2014, a total of 286,000 women are recorded to have availed of the surgery in the United States according to the American Society of Plastic Surgeons making the operation to be one of the most-common cosmetic surgery in the country.

Read more:

Wednesday, November 11, 2015


Background: Among aesthetic surgery procedures, abdominoplasty is associated with a higher complication rate, but previous studies are limited by small sample sizes or single-institution experience.
Methods: A cohort of patients who underwent abdominoplasty between 2008 and 2013 was identified from the CosmetAssure database. Major complications were recorded. Univariate and multivariate analysis was performed evaluating risk factors, including age, smoking, body mass index, sex, diabetes, type of surgical facility, and combined procedures.
Results: The authors identified 25,478 abdominoplasties from 183,914 procedures in the database. Of these, 8,975 patients had abdominoplasty alone and 16,503 underwent additional procedures. The number of complications recorded was 1,012 (4.0 percent overall rate versus 1.4 percent in other aesthetic surgery procedures). Of these, 31.5 percent were hematomas, 27.2 percent were infections and 20.2 percent were suspected or confirmed venous thromboembolism. On multivariate analysis, significant risk factors (p < 0.05) included male sex (relative risk, 1.8), age 55 years or older (1.4), body mass index greater than or equal to 30 (1.3), multiple procedures (1.5), and procedure performance in a hospital or surgical center versus office-based surgical suite (1.6). Combined procedures increased the risk of complication (abdominoplasty alone, 3.1 percent; with liposuction, 3.8 percent; breast procedure, 4.3 percent; liposuction and breast procedure, 4.6 percent; body-contouring procedure, 6.8 percent; liposuction and body-contouring procedure, 10.4 percent).
Conclusions: Abdominoplasty is associated with a higher complication rate compared with other aesthetic procedures. Combined procedures can significantly increase complication rates and should be considered carefully in higher risk patients.


The FDA has approved the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) as a treatment for patients with BRAF-positive metastatic or unresectable melanoma, based on an extension in progression-free survival (PFS) in the phase III coBRIM study.

In the data submitted to the FDA, the median PFS with the combination was 12.3 versus 7.2 months for vemurafenib alone (HR, 0.58). At a 17-month analysis, 65% of patients receiving the combination remained alive compared with 50% for vemurafenib. The objective response rate (ORR) with the combination was 69.6% compared with 50% for vemurafenib alone.

"As we continue to advance our knowledge of tumor biology, we have learned that cancer cells have a remarkable ability to adapt and become resistant to targeted therapies. Combining two or more treatments addressing different cancer-causing targets may help to address this challenge," Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. "Today’s approval provides a new targeted treatment that, when added to vemurafenib, demonstrates greater benefit than vemurafenib alone in patients with BRAF mutation-positive melanoma."